Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

April 27, 2021

NASDAQ US Health Care Life Sciences Tools and Services earnings 63 min

Earnings Call Speaker Segments

Juliet Cunningham

executive
#1

Good afternoon, everyone, and thank you for joining the earnings call covering our first quarter of 2021. On today's call, we'll go over the financial results that were issued following the market close, and we'll also provide commentary regarding our commercial activity; after that, we'll open things up for a question-and-answer session. Should you not have had an opportunity to look at the earnings release, you can locate it within the Investor Relations portion of our website, illumina.com. With Illumina today are Francis deSouza, our President and Chief Executive Officer, along with Sam Samad, our Chief Financial Officer. Francis is going to give an update regarding the state of Illumina's business, and then Sam will walk through our financial results. This call is being recorded, and the audio portion will be made available in the Investors section of our website; it is our intention that all forward-looking statements about our financial results and commercial activity that are made on today's call be protected under the Private Securities Litigation Reform Act of 1995. Forward-looking statements carry risks and uncertainty. Actual events or results could differ materially from those projected or discussed. All forward-looking statements rest upon information currently available, and Illumina undertakes no obligation to update these statements. To gain a better understanding of the risks and uncertainties that might cause actual results to differ, we point you to the documents Illumina files with the Securities and Exchange Commission, including Illumina's most recent Forms 10-Q and 10-K. With that, I'll now hand the call over to Francis.

Francis deSouza

executive
#2

Thank you, and a pleasant afternoon to everyone. During our pre announcement, we noted that Illumina experienced a highly successful beginning to 2021, achieving a milestone of $1 billion in quarterly revenue for the very first time in the company's existence. Revenue for the first quarter reached $1.093 billion, representing a 27% increase over the same period last year and a 15% rise from the previous quarter. Our sequencing business performed particularly well, climbing 29% year over year, largely fueled by quicker expansion in our foundational operations, as both clinical and research clients surpassed their activity levels from before COVID. In addition, we are observing worldwide spending on building genomic epidemiology systems to fight COVID-19 and to watch for potential future pathogen outbreaks. Now I want to walk through a few more Q1 highlights, platform by platform. Starting with the high throughput side: NovaSeq accounted for a big chunk of that outstanding result, posting its best first quarter placement numbers ever, which is pretty impressive given that it's now in year five since we brought it to market. The benefits of our 1.5 reagents keep showing up, bringing in fresh high throughput customers while also driving further switches among our installed HiSeq base. Growth also came from our mid-throughput lineup, where consumables revenue rose 23% year over year. NextSeq 1000 and 2000 kept up their momentum, and NextSeq 550 also turned in a solid showing. One thing we noticed was more customers moving up from the Illumina benchtop sequencers they already owned to the NextSeq 1000 and 2000. On the clinical side, new NextSeq 550 placements keep coming, and NextSeq Dx just had its biggest quarter for shipments so far. In China, the instrument got NMPA approval during Q4, and adoption is strong in hospitals as we partner with IVD developers such as Burning Rock, Biosan and MatriDx to deliver complete clinical solutions. Also, through our strategic partner R-Pharm, NextSeq Dx obtained medical device registration in Russia in March, which lets more patients throughout Russia access next-generation sequencing in clinical settings. Revenue from our low throughput portfolio came in strong once more this quarter, up 33% compared with the same period a year earlier, driven by solid gains in both sequencing consumables and instrument shipments during Q1. Consumables and instrument placements for MiSeq, MiniSeq and HiSeq each rose on a year-over-year basis and sequentially as well. For customers new to NGS, our low-throughput platforms remain an attractive entry point, and the range of use cases keeps expanding. Take Blue & Blue <<inaudible>>, an interesting example — this startup applies our technology to developing cell cultured seafood, which supports sustainability and oceanic diversity. On top of that, these instruments are essential in fueling localized COVID surveillance programs around the world. Now let's move to our Clinical and Research and Applied segments. Sequencing consumables brought in $695 million in total revenue, a 26% increase compared to the same period last year. That shows robust demand for sequencing in both the Clinical and Research segments. More than 44% of the sequencing consumable shipments we made during the first quarter of 2021 went to clinical customers. Clinical testing posted substantial growth, with consumables rising 35% year-over-year. COVID surveillance is not part of these figures—it gets reported under our Research and Academic segment. Oncology testing expanded at a quicker pace than our overall clinical rate, which makes it our largest clinical category as well as the one growing fastest. What's driving that momentum: our customers obtained wider reimbursement coverage for NGS-based testing—particularly comprehensive genomic profiling, or CGP, which is used in therapy selection—along with some of the first reimbursement wins for sequencing-based monitoring tests. Our RUO comprehensive genomic profiling assay, TruSight Oncology 500, kept up its momentum during the quarter, bringing in more than 20 additional customers. In February, the Belgian Society of Medical Oncology said it would adopt TSO 500 for a nationwide pilot assessing CGP use among patients with advanced metastatic cancer. As a top distributable CGP assay, TSO 500 remains an appealing option for our pharma collaborators. Last week we unveiled a promising new collaboration with Kartos Therapeutics aimed at creating a TP 53 companion diagnostic, which extends the TruSight Oncology portfolio into blood cancers. Outside of CGP, we saw encouraging progress this quarter in applying whole genome sequencing to cancer care. Chief among these: a New England Journal of Medicine paper from our partners at Washington University, St. Louis, demonstrated that among the AML and MDS patients examined, whole genome sequencing with Illumina technology yielded more accurate findings in less time and at comparable cost versus standard methods such as fish or karyotyping. On the reproductive health side, the ripple effect of ACON guidance broadening NIPT coverage for every pregnancy produced a third straight quarter of growth both year-over-year and sequentially. Here in the U.S., two big payers—Anthem and Blue Cross Blue Shield of Minnesota—widened their coverage rules to encompass twin pregnancies just last month. Then in March, we shared results from our pioneering risk-sharing, real-world study alongside Harvard Pilgrim, which showed offering NIPT to all pregnant women is cost effective. Such studies strengthen the growing push for wider NIPT access. Overseas backing for NIPT coverage keeps expanding too, driving continued swift uptake of our CE-IVD marked NIPT kit. Italy and Sweden, for instance, delivered good news, with new coverage requirements getting approved during the first quarter of 2021. Shifting to genetic disease testing: clients are selecting Illumina's highly accurate, scalable sequencers, and our growth rate here outpaced the company's rate in Q1. On top of that, we continue to receive new positive coverage decisions. During this quarter, two of Germany's largest health insurers announced they will cover whole genome and whole exome sequencing for rare disease, benefiting their combined membership of over 10 million people. Meanwhile, Geisinger here in the U S expanded its coverage to include epilepsy and cerebral palsy. Studies continue to demonstrate a 40% to 68% diagnostic yield for kids who are suspected of having a genetic disease, with whole-genome sequencing used as a first-tier test. As coverage for these tests widens, more patients will receive faster diagnoses and better care. Let's move on now to our research and academic segment. During the quarter, we achieved robust expansion relative to the equivalent period a year earlier, driven by most of our research and academic clientele coming back to the laboratory. Governments worldwide have become more conscious of how vital genomic pathogen surveillance is in combating infectious disease, thanks to the pandemic and newly appearing variants of concern; investment is occurring across the globe to build pathogen surveillance infrastructure for handling outbreaks and enhancing health results, which encompasses sequencing tools needed to track how pathogens spread, the rise of variant strains, and developing resistance to drugs or vaccines. Within the United States, funding of $1.7 billion is provided through the American Rescue Plan Act for the CDC so it can boost sequencing capacity for detecting viral mutation and circulation; across Europe, a commitment of €123 million was announced by the EC to fight COVID variants; and in India, authorities introduced the Indian SARS-CoV-2, Genomic Consortia, intending to sequence 120,000 viral genomes within the coming four months. Roughly $55 million of additional revenue during the first quarter came from this spending on sequencing for national genomic surveillance efforts, made up of $35 million from instrument placements plus $20 million from sequencing consumables. With nations everywhere still fighting the pandemic, we anticipate that investment in genomic pathogen surveillance will keep growing to broaden national genomic epidemiology capabilities.

Francis deSouza

executive
#3

Although COVID surveillance is the first thing this infrastructure is aimed at, there are lasting needs over the longer term as well, such as monitoring novel natural pathogens that may appear down the road, bioterrorism, resistance to antimicrobial drugs, and infections picked up in hospitals, plus figuring out how the genetics of a host can influence how likely an infectious disease is and how severe it becomes. Demand for our sequencing has definitely been driven up by the pandemic, but we also think it has created a fresh baseline of awareness and build out of infrastructure that will underpin ongoing activity. Even as we navigate the COVID-19 pandemic, we are witnessing faster movement in a number of population genomics initiatives, which extends our footprint within national health systems across the globe. Within the US, all of us increased sample volumes during Q1 to a level we anticipate carrying on through 2021; within Japan, the Tohoku Medical Megabank Organization picked Illumina sequencing for a multigenerational study of 40,000 samples happening this year; during February, Egypt revealed the first population genomics effort in Africa, launching their Egyptian genome project; that initiative aims to build a map of the Egyptian human genome, with the objective of bringing the nation into precision medicine. Big population health efforts are one solid illustration of how we concentrate on bettering the health of patients, communities and our planet. Earlier this month, we released our second annual CSR report, which lays out our particular commitments toward making our world better. You can find this 2021 report on our website, and key highlights include: greater transparency regarding U.S. diversity demographics, planning for climate resilience, disclosure of trade group membership and assurance of data on energy and emissions. We welcome ongoing investor input regarding how our environmental, social and governance programs develop. Advancing human health sits at the core of Illumina's tenets, which leads me to GRAIL. We are happy with how GRAIL is progressing and stay dedicated to seeing the GRAIL acquisition through to completion. GRAIL recently shared positive data from its CCGA 3 study at the American Association for Cancer Research Annual Meeting, and anticipates launching Gallery, its breakthrough multi-cancer early detection screening test, during Q2. Among the many reasons behind our decision to acquire GRAIL was speeding up patient access to breakthrough multi-cancer early detection blood tests, which have the potential to save tens of thousands of lives. We remain dedicated to backing all our customers and firmly believe our purchase of GRAIL is pro competitive. We anticipate the acquisition will speed up the early detection of cancer market overall; we observed a comparable dynamic unfold in the noninvasive prenatal testing market, where, following Illumina's entry, the market expanded and prices fell, which made these important tests reachable for a far bigger population of pregnant women. And now I'll hand things over to Sam.

Sam Samad

executive
#4

To pick up where Francis left off, our first quarter top line climbed 27% from the same period a year ago, hitting $1.093 billion. That was powered by a 29% increase in sequencing and 15% growth in microarrays. We set revenue records in every region, which pushed us past the $1 billion mark in a quarter for the first time ever. Total sequencing revenue hit a new peak, posting first quarter revenue of $979 million, up 16% from the previous quarter and accounting for 90% of total revenue. Sequencing consumables revenue rose 26% versus the prior year period, fueled by robust growth in clinical testing and demand for NovaSeq version 1.5 flow cells. To build on what Francis mentioned, the bulk of our clinical and research clients are now running at levels exceeding their pre-COVID activity. During Q1, initiatives for tracking COVID-19 contributed about $20 million to our sequencing consumables top line. We also saw an approximate $20 million lift in that same category because of when customers chose to place their orders in the first quarter. Revenue from sequencing instruments climbed 123% compared with the same period last year, hitting $176 million in Q1, a result that demonstrates robust momentum in all instrument segments. Our first quarter marked another successive period of record shipments for mid-throughput systems, driven by impressive uptake of the NextSeq 1000 and 2000. Roughly $35 million in additional instrument revenue came from COVID surveillance efforts, as certain customers expanded their capacity for genomic epidemiology. Here's how that section of the call came across: sequencing service and other revenue fell 16% from the same period a year earlier, which was in line with what we had anticipated, and the reason is the IVD partnership revenue that we recognized during the prior year period. On a sequential basis, sequencing service and other was about flat. Now, moving to how we did by region: the Americas generated $562 million in revenue, up 18% versus the prior year period. What drove that growth in the region was strong sequencing product revenue from clinical customers in oncology, reproductive health and genetic disease testing, along with contributions from genomic epidemiology initiatives connected to COVID surveillance. Those gains were partly offset by lower IVD partnership revenue, which we had expected. In EMEA, revenue came in at $305 million, representing 38% growth year-over-year. In EMEA, results got a boost from robust sequencing demand tied to clinical testing uses, which lifted sequencing consumables revenue above what we had projected for Q1, along with instrument demand from research clients—among them programs focused on COVID surveillance and genomic epidemiology. In Greater China, revenue reached $127 million, up 51% from a year earlier and 32% quarter over quarter, reflecting sustained momentum in sequencing revenue fueled by clinical expansion across the region and rising hospital demand, helped by the successful introduction of NextSeq 550Dx. And in APJ, revenue came to $99 million, rising 29% both year over year and sequentially, powered by growth in sequencing consumables revenue from clinical applications including oncology, reproductive health, and genetic disease testing, plus purchases made at the close of the fiscal year. Now, turning to gross margin and operating expenses—I'll be walking through our non-GAAP figures, and those do factor in stock-based compensation. I'd really suggest you take a look at the GAAP reconciliation for these non-GAAP metrics; it's included in the release we put out today, as well as in the supplementary data you can find on our site. Our non-GAAP gross margin came in at 70.5%, which is a sequential gain of 360 basis points, driven by better fixed cost leverage as volumes rose, along with a one-time inventory write-down that occurred in Q4 of 2020. Compared to the prior-year period, non-GAAP gross margin fell 250 basis points, mainly because of IVD partnership revenue booked in last year's quarter, along with product mix and elevated freight costs tied to the COVID-19 pandemic, though these were partly offset by fixed cost leverage from higher volumes. At $420 million, non-GAAP operating expenses rose $81 million versus a year ago, matching expectations, reflecting greater performance-based compensation, a larger headcount, and more project spending in the quarter. Sequentially, non-GAAP operating expenses edged lower, thanks to the extra week in Q4 2020, partly offset by greater variable compensation costs in Q1. Non-GAAP operating margin reached 32.1%, compared with 20.9% in the fourth quarter of 2020. On a quarter-over-quarter basis, that improvement came in above what was expected, driven by higher revenue, better gross margin, and the fixed cost absorption that followed. Non-GAAP other expense totaled $3 million, down $23 million from the prior quarter, which is what we had signaled. That was due to fourth-quarter gains on short-term investments we sold as we shifted our portfolio around in preparation for the GRAIL acquisition funding we expect to make. Interest income also came in lower in the first quarter. Non-GAAP tax rate was 20.3%, up versus last quarter, which reflects tax expense on earnings of certain foreign subsidiaries that are no longer indefinitely reinvested — due in part to capital needs associated with funding the anticipated GRAIL acquisition. GAAP net income for the first quarter of 2021 was $147 million, or $1 per diluted share, while non-GAAP net income came to $278 million, or $1.89 per diluted share. Turning to cash flow and balance sheet items. Operating cash flow totaled $282 million, with DSO at 43 days versus 50 days last quarter, reflecting revenue linearity. Capital expenditures for the first quarter of 2021 were $42 million, and free cash flow was $240 million. No common stock was repurchased during the first quarter; we finished the year with roughly $4.6 billion in cash, cash equivalents and short-term investments. In the first quarter, we collected approximately $1 billion of proceeds from bond issuances to fund the anticipated GRAIL acquisition. During the quarter, our weighted average diluted share count came in at roughly 147 million. Turning now to our 2021 guidance: for the full year, we anticipate revenue growth of 25% to 28%, which works out to $4.05 billion to $4.15 billion. Taking the midpoint of that guidance, it amounts to an increase of roughly $858 million — a substantial jump over what we had been expecting earlier in the year. For full year 2021, using the midpoint of our revenue guidance range, we now project sequencing revenue will rise approximately 29% compared with the prior year, fueled by robust orders and instrument placements. That figure includes growth of about 30% in sequencing consumables versus 2020, powered by NovaSeq version 1.5 Reagent along with expansion in clinical markets. For our sequencing systems, we're looking at year-over-year growth of about 50%. That's fueled by NovaSeq units going to customers who are either new or operating at high throughput, plus ongoing HiSeq transitions, along with mid-throughput interest in our NextSeq lineup. When it comes to NovaSeq, we think pull-through will come in near the top of that $1.1 million to $1.2 million band we laid out at the start. Compared with 2020, we're anticipating an increase of around 5%. For the full year, we anticipate non-GAAP gross margin climbing above where it stood in 2020, driven by better leverage on greater volumes, though this will be partly counterbalanced by product mix and IVD partnership revenue during the first quarter of 2020; our updated outlook for 2021 non-GAAP operating margin sits at about 26.5%, which mirrors our raised revenue projections along with our continued dedication to funding research and development. Our attention remains fixed on steadily enhancing operating margin leverage within our core business as time goes on. We anticipate non-GAAP other income coming in roughly $60 million beneath 2020, owing to the gains we booked in the fourth quarter of 2020, reduced interest income from shorter duration investments as we prepare for the GRAIL acquisition to close, and interest expense tied to our recent bond issuances. For non-GAAP earnings per share, we're looking at $5.80 to $6.05, while GAAP earnings per share should land between $4.72 and $4.97. Diluted shares outstanding for 2021 are projected at roughly 148 million. Turning to the second quarter of 2021, we anticipate revenue rising about 60% year-over-year, helped by the wider economic rebound and momentum in our core business. We're expecting non-GAAP gross margin to be up year-over-year thanks to larger volumes and the leverage that comes with them. On a sequential basis, non-GAAP gross margins should dip slightly, reflecting mix along with extra investments needed to back the volume growth that exceeded our expectations. Non-GAAP operating expenses rose substantially both year-over-year and sequentially, driven by investments supporting business growth and research and development, plus compensation-related costs. Non-GAAP other expense should be somewhat unfavorable sequentially relative to the first quarter. The non-GAAP tax rate is expected to come in a bit lower year-over-year. Taking all this together, we project non-GAAP earnings per share between $1.30 and $1.35 for the quarter, with GAAP earnings per share between $1.21 and $1.26. I'll now return the call to Francis for his closing comments.

Francis deSouza

executive
#5

Thanks, Sam. 2021 has gotten off to a really impressive beginning for Illumina, and there's no question that momentum keeps growing among our customers around the world. Over these past couple of days, at our inaugural annual customer conference, we saw just how diverse and strong our expanding community is. Roughly 8,500 individuals signed up to hear from the foremost pioneers in genomics and healthcare across the globe, among them Jennifer Doudna, Francis Collins, Bill Gates, Frances Arnold and James Suhail. Subjects covered included genomics' vital part in the fight against the pandemic, establishing genomics as a core piece of a national standard of care, bringing together multiomic readouts, and tapping the potential of AI and machine learning in oncology, along with others. Whether it's taking on cancer or diagnosing genetic disease, or characterizing the pandemic, the transformative effect genomics will have on human health keeps speeding up, and here at Illumina, we take pride in the essential part our customers, partners and employees are playing in bringing that about. At this point I'll ask the operator to open things up for Q&A.

Puneet Souda

analyst
#6

Absolutely, Francis — I appreciate those questions. To start with the first one: when we talk about that 25% to 28% guidance for the year, how much COVID surveillance work is actually factored in? What I think you're really asking is about the COVID surveillance opportunity and how quickly it unfolds as the epidemiological infrastructure gets built out — what's the timing on that? And it's worth noting that COVID is still widespread in various regions globally, vaccinations across the U.S. are picking up pace, and the administration is putting over $1 billion into sequencing efforts. So I'm curious how much of that is reflected in this year's number? And what kind of tail should we expect over the longer term? Next up, my other question relates to GRAIL. What are the upcoming steps in the process for the FTC as well as the European Commission Directorate General? What does that sequence involve? And clearly, you're suggesting a close in the second half. So I'm just curious about what the — what some of those upcoming steps might be? Thanks.

Francis deSouza

executive
#7

Fantastic. Well, I appreciate your questions, Puneet. Let me begin by noting that it is — it's thrilling to observe how the world is kind of progressing toward establishing a pathogen surveillance infrastructure. As you're aware, Puneet, this has been a topic of ours since the start of last year. We've kept saying that beyond testing, a genomic epidemiology infrastructure is truly what's needed. So it's heartening to watch that unfold globally and to see the major pledges made here in the U.S. Now, addressing your question about what we're incorporating into this year: the bulk of the expansion within that 25% to 28% range stems from our core business. Our modeling for this year went like this — we anticipate modest input from the surveillance infrastructure throughout the entire year. During the first quarter, we did observe certain investments being made. That resulted in a $35 million bolus tied to instrument purchases, which came through in Q1, allowing us to establish a portion of that infrastructure, and we also noticed some consumables-related infrastructure; therefore, when it comes to how we're modeling things, we'll keep assuming there will be some consumable buying throughout the remaining portion of the year, though additional infrastructure spending should not be significant. As for how we anticipate this unfolding, bid commitments are already being seen even within the U.S. in connection with the American Rescue Plan, and we anticipate that a portion of those funds will be freed up near the end of this year before gaining more momentum next year. What's notable here is that although this infrastructure will prove quite useful for combating the pandemic, it genuinely represents a lasting initiative on the part of the countries implementing it. Their focus is on building, over the long term, a pathogen surveillance system rooted in genomics — one meant to help address this pandemic and to get ready for whatever comes next, be it a naturally occurring outbreak, bioterrorism, newly appearing antimicrobial resistance, or infections picked up in hospitals. So, as you're suggesting, we do anticipate some tail from this. This isn't something that plays out just in the current year — in fact, we've built hardly any of it into this year's model — rather, it's something that unfolds through next year and beyond. That's the way we're approaching it in the model. Naturally, we'll be sure to pass along more specifics to you as they emerge. Regarding GRAIL, as I mentioned, our commitment to going after the GRAIL acquisition stands. Within the U.S., that translates into bringing our case before a district court. In addition, we're cooperating with the European Commission as it conducts its review of the GRAIL acquisition. Our feeling remains that the facts favor us and the law favors us. And our expectation remains that the deal will be completed, and completed during the back half of this year.

Doug Schenkel

analyst
#8

Hi there, good afternoon, and thanks for fielding my questions. I'd like to cover two areas — first antitrust along with strategy, and second, the philosophy behind guidance. Regarding antitrust and strategy, as everyone is aware, during the past 2 years Illumina encountered regulatory difficulties concerning the PacBio purchase, which has since been dropped, plus the intended GRAIL acquisition. And keeping in mind all that you mentioned both in your prepared comments and in your answer to Puneet regarding GRAIL, I'm curious, first, given these events, how are your strategic opportunity criteria shifting? And second, what process modifications are you implementing? Clearly you believed your approach to these deals was sufficient, yet each turned out far more difficult than anticipated. So presumably you're adjusting in response. I believe it would be valuable to learn about those adjustments. Then, regarding the philosophy of guidance, how confident would you say you are right now in your numbers for this year? Your targets strike me as quite logical, despite the fact that the growth figures are indeed enormous. And you mentioned — I believe the figure was $1.4 billion of backlog coming in during Q2. That being said, as we're all aware, the world remains unpredictable as we emerge from 2020. And looking back at 2019, that proved a difficult period for Illumina when measured against targets it set itself. With all of that in mind, I simply — I believe it would be valuable to hear what philosophy you're using for guidance this year. Also, do you still believe you're leaning toward the more cautious end of the spectrum? Thank you.

Francis deSouza

executive
#9

Excellent. Hey, Doug, let me address both portions of what you asked. I'll begin with our approach to acquisitions, particularly addressing any effect from what we went through with the FTC and how that shifts our philosophy around power moving forward. After that I'll discuss guidance for the remainder of the year. And Sam might chime in at that point as well. So to start, by way of saying, if you examine what we've acquired during the past 2 years, we have — we tried to acquire PacBio, I believe that was 3 years back when we started it, and clearly we couldn't get that cleared by the FTC. Yet we did manage to close the Edico purchase, which proved a tremendous success in terms of integrating the DRAGEN technology into our sequencers, and it has been extremely well received among our customers, and so that truly generated positive momentum on the informatics side; we likewise finished, for instance, the Enancio acquisition and incorporated lossless data compression technologies and capabilities into our — into our sequencers too; and so what we observe is that we've succeeded when it comes to purchasing innovative technologies that we can integrate into our sequencers and bring to market. At the same time, though, we're noticing that because our sequencers have become so popular within our primary market, there is still effort required on our part regarding certain larger acquisitions. So first, I believe we'll keep scanning the market, seeking purchases that represent smart technology tuck-ins, along with, occasionally, bigger acquisitions that are worthwhile. Our view remains that vertical acquisitions fall comfortably inside what we consider acceptable, and that is the path we will pursue in court regarding the GRAIL acquisition. We likewise acknowledge that because of the scale we've reached and because of where we stand in the market, additional effort will be needed from us when it comes to teaching regulators about our operations and ensuring they understand our operations thoroughly even prior to any acquisition we make. So that's one more lesson from these last 2 years. From a strategic standpoint, though, I'd say we remain focused on ensuring we seek out opportunities to deploy capital, whether internally or externally, that produce the greatest shareholder value. That focus is completely unchanged; regarding our guiding philosophy for the year, I think you raised a few key points. It's a balanced perspective, in our view, which on one hand acknowledges that as we enter the year and come off the quarter, we carry an enormous amount of momentum within our core business; so when you examine both the clinical portion of the business and the research portion, we're witnessing genuine strength, and that is reflected in the revenue figures we posted in Q4, but clearly also in Q1, it's reflected in the orders figures, it's reflected in the instrument, the enormous instrument growth rate we saw year-on-year in Q1. So an enormous amount of momentum within our core business. On top of that, we're witnessing highly encouraging signals from the COVID surveillance add-on business. So on one hand, with that enormous momentum carrying us through the remainder of the year, but as you noted, uncertainty persists since we're still contending with the pandemic. And so we're still monitoring how the pandemic unfolds while countries struggle with the third wave and a fourth wave, and that might affect people's capacity to enter the labs or perform the clinical sequencing that they that they require. And so we're balancing those two things. And the figures we released, even though they are large figures, we have confidence in, and we believe it achieves that suitable balance. I don't know, Sam, whether you have anything further to add.

Sam Samad

executive
#10

Absolutely, Francis, you've got it. Let me keep this short and perhaps tack on one or two additional remarks. First off, regarding the range we've provided for guidance, our confidence level is quite high. For the year ahead, it's a well-balanced perspective. Doug, a major source of that assurance comes from how robust our core business is; the core business is showing incredible momentum, and that bolsters the confidence we hold. The sole possible headwind I'd flag, or risk, would be the unpredictability surrounding the pandemic, which Francis brought up.

Tycho Peterson

analyst
#11

Hi there, and thanks. I have a few quick items. First, on how well instruments are performing, Francis, I'm interested to know — now that labs are resuming operations, what portion of this is essentially spending that was postponed from last year catching up? Clearly, your full-year guidance sits above the Street's expectation. So perhaps there's no pull forward at all, but I'd like your thoughts on it. Then regarding the COVID work, I believe on the prior quarter's call you mentioned capturing more than 70% of those projects. Could you discuss what's happening competitively there? Also, when we consider your installed base of instruments, which platforms do you believe will be best suited for the surveillance applications that continue going forward? And then a question about competition. There's what you might call a third wave of sequencing firms, with common single element among them. I'm interested in how you see the competitive landscape changing as you look ahead a couple of years. And finally, for Sam, on FX contribution — I didn't catch that, so I'm curious whether you could break it out for the quarter. Thanks.

Francis deSouza

executive
#12

Wonderful. Thank you, Tycho. Alright. There were quite a few questions there, so let me be sure I address each one. I'll begin — so to start, you inquired about the momentum we're seeing from the instrument portfolio, so let's discuss what's behind it. After that, you raised COVID surveillance and noted that we'd said we would account for roughly 70% of the surveillance testing performed, and asked how things have unfolded since we last discussed those figures, plus which instruments are most effective for that purpose. Then there was your request for thoughts on the competitive landscape. Okay. So let me begin with instrument momentum. Yes. We mentioned that we experienced tremendous instrument momentum in Q1, with revenue from sequencing instruments in Q1 more than doubling compared with the same period a year earlier — an enormous level of momentum. What's behind it is momentum in the core businesses, on both the clinical and research sides. We discussed the momentum observed on the clinical side in oncology testing. As a segment, oncology testing is now not just our biggest clinical segment, but in fact our segment growing the fastest; and many factors underlie the momentum in oncology, correct? And more widely across the clinical segment. Among the major factors is that we observed a very substantial advance in reimbursement spanning multiple clinical segments during the past year. Genetic disease testing, oncology, NIPT; and as a result, the addressable market — meaning the number of people able to access tests with reimbursement — grew over the past year. That, in turn, is fueling greater business for our clinical customers, and that is fueling what they purchase. There are additional forces at work here, such as how well our clinical operations are doing in China, plus the authorization we got from the NMPA for NextSeq, and that is fueling growth in instruments. So this isn't a matter of catching up. The market just keeps getting bigger, correct? When reimbursement increases, the addressable market gets larger. As more products get cleared, the addressable market gets larger too, in the sense of what we can do to put instruments into hospitals, say, in China; and that is genuinely what is behind the instrument momentum. And clearly, that is very thrilling, since it bodes well for consumable revenue down the road from every instrument we placed in Q1; regarding COVID, what we have said is that if you check GISAID or NCBI, you can follow, by looking at how many genomes get deposited, which platforms were used to run them. And so I believe a useful blog appeared within the past 2 days. I believe Keith Robinson wrote a genomics clinic blog; and he ran an analysis, and it comes quite close to our own, which indicates our share there is roughly — it has risen roughly 79%. Now, out of all the genomes in GISAID, they have been generated on Illumina platforms. I think the next highest is O&T at roughly 17%, I believe, and it drops off from there. And so it's comparable, though perhaps slightly better than what we mentioned previously. As for the instruments, a wide variety of instruments are being utilized for surveillance. Clearly, NovaSeqs are a very well-liked instrument among the high-volume shops. But we are also seeing plenty of NextSeqs and MiSeqs in use. And so it is that mix, so to speak, that is performing very strongly. On the competition front, competition always exists in the market. As you might expect, a market this early and expanding this fast will keep drawing investment dollars. So just as you were looking at some newer entrants that will be putting money in over the next year or two, and I think you named a few of them, there are obviously companies already in the market today that we go up against; but that has been the case annually; so I would say each year, a fresh set of venture-funded rivals appears; and it falls to us to keep innovating and give our customers more value.

Sam Samad

executive
#13

Yeah, regarding FX, Tycho. So in Q1, I'd say that versus Q1 of 2020, the FX tailwind added roughly 3% as a year-over-year benefit, and the main drivers there were the euro and the RMB — so those currencies strengthening. When we look at the full year, we expect that benefit to ease as we move ahead, so certainly more of it landing in the first half than in the second half. And for the full year, we're looking at, I'd say, about 2% in terms of the total benefit from currencies compared with 2020.

Tycho Peterson

analyst
#14

Okay. Thank you.

Francis deSouza

executive
#15

You're welcome.

Sung Ji Nam

analyst
#16

Hello, and thank you for taking my question. Francis, would you be able to discuss oncology testing? Clearly, there's a great deal of momentum in that area, and you credited it to improved reimbursement along with other positive developments. I'm just wondering — since you have such broad visibility across the diagnostic companies operating out there — whether you are observing any sort of recovery from the backlog of screening and cancer diagnosis delays from last year. I'd really like to hear your perspective on that and how much insight you have into it.

Francis deSouza

executive
#17

Yes. As you mentioned, clearly we collaborate very closely with our customers, and we have outstanding customers such as FMI and Gardens and others in oncology testing. From where we sit, if you happened to be operating in the liquid biopsy arena — meaning you provide a blood-based test — you were in fact more resilient throughout the pandemic than a lot of other categories of clinical testing. Consequently, a number of our customers came up with quite creative approaches, whether that meant mobile phlebotomy units or enabling at-home access to the test for certain patients. That becomes feasible when you have a blood test. So in oncology testing, I believe one of the defining narratives of the pandemic will turn out to be an acceleration in the embrace of liquid biopsy, and I view that as a lasting shift. My expectation is that as we emerge from the pandemic, you will keep witnessing growth in liquid biopsy, since people have come to understand that beyond obtaining high-quality results, it represents a far more patient-friendly approach to testing compared with a tissue-based test. So if it's feasible, you'll see liquid biopsy emerge as the preferred route. What does that imply? There really isn't a great deal of catch-up left to happen in Q1, given that you witnessed how resilient liquid biopsies were. And by a wide margin, I'd say the primary forces behind the momentum in oncology are items such as: first, broader reimbursement for things such as CGP; second, the ongoing arrival of new therapeutics that take advantage of genomic biomarkers. That is also manifesting through the companion diagnostic partnerships we are entering into for TSO 500. And then there's the availability of products such as TSO 500 — from us, from our partners — that generate offerings which make it simpler for labs to establish those steps; so I believe every one of those elements is fueling the lasting momentum in oncology testing, and perhaps there's a modest amount of catch-up, but honestly, if any existed, it was minimal, in my view.

Max Masucci

analyst
#18

Hello. I appreciate you answering our questions, and congratulations on a strong beginning to the year. So building on something asked earlier: the wording used by the FTC when it challenged the GRAIL acquisition appears tightly aimed at blood-based multi-cancer screening, and that's merely one among several emerging clinical applications in the wider liquid biopsy space, which aims to address a broad variety of cancer types. Given that, while the FTC continues reviewing the GRAIL deal, should we reasonably expect you to stay active on the M&A side? And should the transaction be stopped, would it be reasonable to expect that any M&A you pursue later would focus on businesses creating clinical liquid biopsy applications meant for only one or a limited number of cancer types, rather than the big multi-cancer prize?

Francis deSouza

executive
#19

Yes. That's a solid point, in that liquid biopsy, or blood-based testing, gets used across multiple kinds of testing in oncology. One kind, as you noted, is multi-cancer early detection, which is what GRAIL does, along with other companies pursuing that in the market. Therapy selection is another area where liquid biopsy gets used. That means helping match patients — cancer patients already diagnosed — with the right therapies for them. We already offer a product, a kit, serving that space; our TSO 500 product is used for therapy selection. A totally separate portion of the market calls for different technology and looks for different things in the blood. So liquid biopsy serves many purposes, but these are quite distinct segments. Each one differs and calls for different technologies within a liquid biopsy approach. The answer is that we will keep evaluating M&A down the road. It will include both technology tuck-ins that help us move our mission and strategic priorities forward, and that might cover a variety of things. Technology tuck-ins are one possibility. It could be seeking capabilities that broaden what we offer within our sequencing offerings. And so we'll keep doing that.

Tejas Savant

analyst
#20

Hi everyone. Evening, and I appreciate you making time. Francis, I've got three questions for you: the first about COVID, the second about arrays, and the third about sequencing services. Starting with COVID — you brought up the surveillance work in India, both in your prepared remarks earlier in the pandemic and again this afternoon. I believe you mentioned roughly 125,000 viral genomes over the coming months. And clearly, funding is also coming in from the U.S. and Europe. Why aren't you anticipating that this type of work will add somewhat more in the near term to that $20 million in consumables contribution during the first quarter? That's my first one. Next, on sequencing services, and this one is aimed more at Sam. Setting aside the $25 million milestone in the year-over-year comparison, quarterly growth was basically flat. Should we be factoring in any offsets for this quarter? And last, on arrays — the business, from both the services and consumables side, actually posted year-over-year growth after a long stretch. Is it reasonable to view the business as having finally bottomed, apart from the normal seasonality you'd expect in 2Q and after?

Francis deSouza

executive
#21

Alright. There are several pieces to that. I'll begin, and we'll spend a bit of time on COVID. The question is, why not more, correct? Because it's obvious that people now widely recognize the value of sequencing for genomic pathogen-based surveillance — for COVID, and also as an acknowledgment that this infrastructure will matter for a great many years ahead. So, why not more? Your other question concerned arrays — have we hit bottom? Alright. Let's take the first one. We firmly believe that what we're building here is durable infrastructure, and that it will be a key component of all national — of major national health systems going forward. We firmly believe this infrastructure will hold value, not only for safeguarding public health, but also from a national defense standpoint. So our expectation is that this unfolds across a decade or more, correct? And in most countries, we will have some form of genomic pathogen-based surveillance going forward. As for how we framed it this year — the way we approached this year was to say that you see a bolus of instrument purchases in Q1, and we expect that to be the majority of instrument buying we should anticipate this year. And we've discussed the fact that many countries — we engaged with them last year, and they purchased some sequencing. So for the remainder of this year, we expect consumable purchases to keep coming. But what we anticipate is what you saw: the majority of instrument buying for what will happen this year has already occurred. There's a chance that additional activity occurs, and what would fuel it is clearly the American Rescue Plan, which involves some extremely large figures. Our view is that figuring out the specifics will require some time. Therefore, although purchases of consumables will occur throughout the year, our expectation is that it won't be until close to the year's end that you begin hearing people ask questions like, alright, where exactly are these 6 Centers of Excellence, what quantity of sequencing infrastructure do they currently possess, and what amount of extra hardware do we require. So from an instruments standpoint, this will be a narrative spanning the latter portion of this year, moving into the following year and further out. That's the way we approached it; should any of this speed up during this year, we'll make sure you're informed. When it comes to arrays, we did observe year-over-year growth to some degree. That business has distinct components. One is the direct-to-consumer piece, and then there's also — and perhaps Sam will speak briefly about how those components unfold.

Sam Samad

executive
#22

Yeah. So I believe how you're describing the stay house is accurate, in that the business is stabilizing, and we're seeing less of a negative — certainly not a negative effect coming from arrays. In fact, we saw them increase in Q1. The reality is, DTC now makes up a very small portion of our business. It's roughly 2% to 3% of total revenues. Back in 2018, DTC contributed a much larger share of overall revenue. So while we're quite happy to see arrays rising in Q1, DTC in particular is a smaller contributor, and we still see our mature arrays, the mature business, whether that's agrigenomics or other applications, continuing to expand as well and it has kept expanding over time. Maybe turning to the last question you had about sequencing services and others, so let me walk through the dynamics there, Tejas. Q1 versus Q1 of last year, we do face a negative headwind tied to a $25 million IVD licensing fee that we had in Q1 of 2020 and that we didn't have in Q1 of this year. So that was a negative. And as you saw, sequencing and other declined 16% for the quarter. As we look at the year, what our guidance assumes is no material licensing fees or IVD fees related to any significant transactions or partnerships, I should say, for the year. So we expect sequencing service and other to be mostly flattish for the year, quarter-over-quarter. And that aligns with our original guidance from back in January.

Derik De Bruin

analyst
#23

Hello, and good afternoon. Hey, I've got a handful of things to ask. So I suppose the opening one relates to your revenue guidance — I have a couple of items there — and also the results themselves. To start: what portion of your HiSeq lineup remains to be upgraded? And regarding the momentum you recorded in the first quarter, how much came from customers who had intended to do upgrades during last year but ended up not doing so? I'm simply attempting to gauge — one, I believe there are plenty of inquiries regarding the instrument momentum. Looking at your guidance, it seems like about $1 billion per quarter across Q2, Q3, and Q4 — and I realize there's likely some conservatism baked into those figures. So my question is, when you consider that back half, why does it appear relatively flat compared to what we've seen historically? Then I have a separate question — could you take us through the complete stock compensation figures for this year, explain how they come together, and how that carries over into 2022? That would really help us understand how to build our model. Thanks.

Francis deSouza

executive
#24

Yes. Thanks, Derik. There are a few things I want to cover — actually three items: first, HiSeq; next, our guide; and last, stock-based comp. I'll begin with HiSeq, then hand things off to Sam for the remaining two. When it comes to the HiSeqs — well, at the point we launched the NovaSeq upgrade path, as you're aware, we mentioned that 850 HiSeq customers existed and that, eventually, we anticipated most of them — the great bulk — would transition to NovaSeq. From 2017 all the way through to the close of last year, the count of units requiring upgrades dropped from 850. After we updated those figures, the number we passed along to you was 320 remaining. That upgrading work carried on through Q1. In my view, it wasn't a lump or a make-up surge. What we saw looked more like a consistent, ongoing pace of upgrades, which is what we've been observing, and we anticipate that pattern persisting across the quarters ahead this year and in the years to come. So upgrades certainly kept happening, yet no massive spike or catch-up burst actually took place. With that, Sam, I'll hand things over to you.

Sam Samad

executive
#25

Sure. On your remaining two questions, Derik, I'll begin with linearity, since that's likely what you mean when you mention the roughly $1 billion quarter. To start, remember that in Q1 we had a pair of items that helped us, and one involved $35 million in instrument purchases tied to COVID surveillance. Our view is that this was a one-time event, essentially infrastructure building. Going forward, at least where COVID is concerned, we don't anticipate meaningful instrument placements. That is reflected in our assumptions and in our guidance assumptions. The second item, which we flagged, was approximately $20 million in consumable purchases, which we describe as catch-up purchases during Q1. Since customers may have been carrying somewhat less inventory, they bought about $20 million more than is typical—not a significant figure, but portions of it—and that is what lifts Q1. That explains why Q2 steps down sequentially. It also explains why neither the year nor the second half exceeds the first half. Another factor keeping the second half from surpassing the first half is UK BioBank, whose sequencing we expect to finish during the second half. In fact, they will conclude that project around Q3. Those are the contributors, and that is why I'd describe our linearity as flattish for this year. As for stock-based compensation, I noted at the start of the year an impact of roughly just over $50 million year over year from stock-based comp. From an expense perspective it is now actually larger, because our performance has also pushed our stock-based accruals—our stock-based compensation accruals—higher. So overall we anticipate greater stock-based comp. On a year-over-year basis, then, it is in fact beyond that $50 million. We have not provided a figure for 2022. It remains too early to discuss stock-based comp for 2022, though that negative impact clearly lessens in 2022 compared with 2021.

Francis deSouza

executive
#26

Sure. Thanks, Sam. And Derik, perhaps I can offer additional detail regarding NovaSeq, since the truth is there's tremendous momentum in that business right now. We mentioned before that during Q4, orders for NovaSeq hit their peak for any quarter since the product first came out in Q1 of 2017. That's quite remarkable given that we're now in NovaSeq's fifth year, correct? So momentum was enormous in Q4, with record orders, again trailing only the launch period. Then in Q1, momentum was once more very strong. We just noted that this was our best placement quarter for a first quarter in any year since NovaSeq became available. So you're entirely correct—there's enormous momentum; what's behind it? I mentioned that no sort of catch-up on upgrades was involved. What's fascinating, and we've pointed this out previously, and it has persisted, is that we're experiencing tremendous strength from customers who are new to Illumina and new to high throughput. That was not something we anticipated at NovaSeq's launch. Roughly half were expected to originate from labs essentially unlocked by the democratization of sequencing that NovaSeq embodies, and that carries on with the release of version 1.5; therefore, what the market tells us is that 1.5 genuinely sparked demand elasticity and served as the accelerant behind those substantial NovaSeq orders in Q4 and the placements observed in Q1.

Patrick Donnelly

analyst
#27

Thanks for taking my questions, everyone. The first one is probably for you, Sam. On the profitability front, there was a fairly encouraging gain relative to the guidance we had 3 months back. Taking a longer perspective, could you discuss the return toward what used to be normal 1 or 2 years ago, considering the recent challenges from COVID, inventory write-downs, and price adjustment — what does the route back to that prior Illumina look like? And separately, regarding mid throughput instruments, could you walk us through pull-through there? What is the appropriate framework for thinking about NextSeq, perhaps for this year and beyond? Any insight on that would be useful.

Francis deSouza

executive
#28

Yes, certainly, Patrick. Thanks for asking. On profitability, as you observed in both our guidance and our Q1 results, clearly we have achieved quite meaningful progress in enhancing profitability or extending the profitability of the business. That aligns with what we have said throughout: as volumes begin to scale, and we experienced considerable momentum in the core business plus some contribution from COVID, leverage is improving. In Q1, operating margins came in above 30%. For the full year, we anticipate roughly 26.5%; and going forward over time, we expect that to rise. What might be the factors behind that and the components involved? Clearly gross margins, which are better than in our prior guidance, and they will keep getting better once we move beyond certain COVID-related items such as elevated freight costs. Clearly, with volumes scaling, gross margin is improving; however, I want to note that we are investing in the business, in manufacturing capacity as well as OpEx. The growth we are witnessing greatly surpasses what we anticipated, and we are extremely encouraged by it; and we need to catch up by investing in infrastructure to match some of the demand we see, both in manufacturing and, as I said, in OpEx, which is why we are committed to it. Yet looking ahead, we are also committed to enhancing leverage over time and returning to historical levels. We remain on that path. We achieved solid progress in only a single quarter, but we remain on that path; regarding mid throughput — was the question mid throughput or low throughput? Sorry, that was the question. Mid throughput. As for throughput, we are not yet at a point where we can disclose what the expectations are for pull-through with respect to NextSeq 2000, NextSeq 1000. It goes without saying — and I realize your question is focused more on consumables — but what I can share is that the pace of placements we're observing for mid-throughput on the 2000 and 1000, plus the 550 DX and 550, is really quite encouraging. Each quarter, we're setting records for placements, and we anticipate sustaining that pace moving forward, and even building on it. So when you're at this point — still in the early phase of rolling out this instrument — and you're witnessing this kind of expansion, it's genuinely difficult right now to assign a consumable pull-through range. That means we need a few more quarters before we're able to do so.

Juliet Cunningham

executive
#29

Okay, thank you all for being here. We’re grateful for your attention and for taking the time. Just a note that a replay of this call will be posted on our site as quickly as we can manage. That brings us to the end of today’s call. We’re eager to bring you an update when we report our second fiscal quarter of 2021. Thanks so much.

Operator

operator
#30

This concludes today's conference call. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.